Yang Yin Fu Zheng Therapy in HBV Associated Hepatocellular Carcinoma
Early Phase 1
Completed
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Drug: Routine medical careDrug: Yang Yin Fu Zheng therapy
- Registration Number
- NCT02927626
- Lead Sponsor
- Beijing Ditan Hospital
- Brief Summary
Clinical research of Yang Yin Fu Zheng therapy in HBV associated hepatocellular carcinoma basing on immune microenviroment.The purpose of this study is to observe the efficacy of routine medical care combined with Yang Yin Fu Zheng therapy for patients belong to HBV-HCC.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 132
Inclusion Criteria
- Confirmed of stage HBV-HCCⅡb、Ⅲa、Ⅲb;
- Ages Eligible for Study: ≤75 years old;
- TCM syndrome is deficiency of both Qi and Yin;
- Confirmed of CHB;
- Surgery cannot be allowed;
- Informed consent from the patient.
Exclusion Criteria
- Patient with other chronic hepatopathy, such as AIH, NAFLD, ALD;
- Serious problem of heart, lung, or kidney with severe dysfunction;
- Pregnant or child breast feeding women;
- Mental or cognitive disorders;
- Participating in other drug trials;
- Who are allergic to the study drug.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Routine medical care Routine medical care - Yang Yin Fu Zheng therapy Routine medical care - Yang Yin Fu Zheng therapy Yang Yin Fu Zheng therapy -
- Primary Outcome Measures
Name Time Method Survival rate 2 years
- Secondary Outcome Measures
Name Time Method quality of life(QOL) 2 years Objective response rate 2 years
Trial Locations
- Locations (1)
Zhiyun Yang
🇨🇳Beijing, Beijing, China